The Delaware Chancery Court ruled this week that it can’t force Fresenius (ETR:FRE) to follow through with its $4.75 billion merger with Akorn (NSDQ:AKRX).
The deal was designed to help Fresenius move into new dosage forms and therapeutic areas, including ophthalmic drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius walked away from the deal in April, citing an investigation that found material breaches of FDA data integrity requirements related to Akorn’s operations.
Get the full story at our sister site, Drug Delivery Business News.
The post Fresenius cleared to jilt Akorn, court rules appeared first on MassDevice.